首页> 美国卫生研究院文献>Frontiers in Systems Neuroscience >A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study
【2h】

A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study

机译:一项新的V1a受体拮抗剂阻断血管加压素诱导的中枢神经系统对情绪刺激的反应变化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: We hypothesized that SRX246, a vasopressin V1a receptor antagonist, blocks the effect of intranasally administered vasopressin on brain processing of angry Ekman faces. An interaction of intranasal and oral drug was predicted in the amygdala.>Methods: Twenty-nine healthy male subjects received a baseline fMRI scan while they viewed angry faces and then were randomized to receive oral SRX246 (120 mg PO twice a day) or placebo. After an average of 7 days of treatment, they were given an acute dose of intranasal vasopressin (40 IU) or placebo and underwent a second scan. The primary outcome was BOLD activity in the amygdala in response to angry faces. Secondary analyses were focused on ROIs in a brain regions previously linked to vasopressin signaling.>Results: In subjects randomized to oral placebo-intranasal vasopressin, there was a significantly diminished amygdala BOLD response from the baseline to post-drug scan compared with oral placebo-intranasal placebo subjects. RM-ANOVA of the BOLD signal changes in the amygdala revealed a significant oral drug × intranasal drug × session interaction (F(1, 25) = 4.353, p < 0.05). Follow-up tests showed that antagonism of AVPR1a with SRX246 blocked the effect of intranasal vasopressin on the neural response to angry faces. Secondary analyses revealed that SRX246 treatment was associated with significantly attenuated BOLD responses to angry faces in the right temporoparietal junction, precuneus, anterior cingulate, and putamen. Exploratory analyses revealed that the interactive and main effects of intranasal vasopressin and SRX246 were not seen for happy or neutral faces, but were detected for aversive faces (fear + anger) and at a trend level for fear faces.>Conclusion: We found confirmatory evidence that SRX246 has effects on the amygdala that counter the effects of intranasal vasopressin. These effects were strongest for angry faces, but may generalize to other emotions with an aversive quality.
机译:>背景:我们假设血管加压素V1a受体拮抗剂SRX246阻断了鼻腔加压素对愤怒的Ekman面部大脑处理的作用。在杏仁核中预测了鼻内药物与口服药物之间的相互作用。>方法:29名健康男性受试者在观看生气的面孔时接受了基线fMRI扫描,然后随机接受口服SRX246(120 mg PO每天两次)或安慰剂。经过平均7天的治疗,他们接受了急性剂量的鼻内加压素(40 IU)或安慰剂治疗,并进行了第二次扫描。主要结果是杏仁核对生气的面孔做出了大胆的活动。次要分析的重点是先前与血管加压素信号传导有关的大脑区域中的ROI。>结果:在随机接受口服安慰剂-鼻内加压素治疗的受试者中,从基线到药物治疗后杏仁核BOLD反应明显减弱扫描与口服安慰剂-鼻内安慰剂受试者比较。杏仁核中BOLD信号变化的RM-ANOVA显示显着的口服药物×鼻内药物×疗程相互作用(F(1,25)= 4.353,p <0.05)。后续测试表明,AVPR1a与SRX246的拮抗作用可阻断鼻内加压素对愤怒面孔神经反应的作用。二级分析显示,SRX246治疗与右颞顶汇合处,前突,前扣带和壳核对愤怒面孔的BOLD反应显着减弱有关。探索性分析显示,鼻腔内加压素和SRX246的交互作用和主要作用在高兴或中性的面部中未见,但在厌恶性面部(恐惧+愤怒)中被检测到,而在恐惧面部中呈趋势水平。>结论 >:我们发现了证实性证据,表明SRX246对杏仁核有作用,可抵消鼻内加压素的作用。这些效果在生气的脸上最明显,但可能会泛滥成其他具有厌恶性的情绪。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号